"Prima BioMed chief executive officer Martin Rogers told BTN he was confident the Phase 3 trial would help get the drug market approval after the company had positive results from its randomised Phase 2a and 2b studies."
And then
"The Phase 2b trial will involve 60 ovarian cancer patients from the United States and Australia"
So they have had positive results from a trial they have not yet completed ???
I know, its probably a typo or miss quote but thought I would throw it out there.
No biggy
Cheers
- Forums
- ASX - By Stock
- IMM
- media exposure
media exposure, page-100
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
40.0¢ |
Change
-0.005(1.23%) |
Mkt cap ! $581.0M |
Open | High | Low | Value | Volume |
41.0¢ | 41.5¢ | 39.5¢ | $1.576M | 3.906M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2506 | 39.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
40.0¢ | 8079 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 62000 | 0.390 |
4 | 33064 | 0.385 |
8 | 91570 | 0.380 |
1 | 100000 | 0.370 |
4 | 24220 | 0.360 |
Price($) | Vol. | No. |
---|---|---|
0.410 | 41895 | 3 |
0.415 | 130388 | 7 |
0.420 | 550003 | 10 |
0.425 | 39700 | 3 |
0.430 | 13701 | 3 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online